Buyer guide
How to Make Bioinformatics Analyses Reproducible and Publication-Ready
What publication-ready bioinformatics looks like and how to avoid reruns that fail from missing versions, seeds, or parameters.
Buyer guide
What publication-ready bioinformatics looks like and how to avoid reruns that fail from missing versions, seeds, or parameters.
| Category | Details | Source |
|---|---|---|
| Microarray analysis reproducibility | Only 2 of 18 published microarray analyses reproduced in principle; 10 could not be reproduced at all | [2] |
| Notebook re-execution success | 5.6% of biomedical Jupyter notebooks with declared dependencies produced identical results on automated rerun (879 of 15,817) | [1] |
| Researcher reproduction experience | >70% of 1,576 surveyed researchers tried and failed to reproduce another scientist's experiment | [3] |
| NIH intramural reproduction attempts | 0 of 5 bioinformatics papers were fully reproduced in an NLM workshop; missing data, software, and documentation cited | [4, 5] |
| NGS Methods documentation gap | Fewer than half of 50 NGS papers provided any software-version or parameter details (via Nekrutenko & Taylor, 2012, cited in Piccolo & Frampton, 2016) | [6] |
| Spreadsheet gene-list errors | 30.9% of PubMed Central articles with supplementary Excel gene lists contain gene-name conversion errors (3,436 of 11,117) | [7] |
| Funder reproducibility expectations | NIH DMS Policy effective 25 January 2023; DMSP must address related tools, software, and code; Wellcome requires data and software needed to replicate analyses at publication minimum | [8, 9] |
The reproducibility crisis in bioinformatics is the gap between published claims and what an independent analyst can actually rerun from available data, code, and documentation. In computational work, reproducibility means getting consistent results from the same data and pipeline; replicability means getting consistent results from new data under the same protocol [10]. Published bioinformatics fails both tests more often than many labs expect.
Ioannidis et al. [2], Zaringhalam & Federer [4], and Samuel & Mietchen [1] found the same pattern: missing data, versions, and documentation block rerun—not the biology. Software defaults, reference builds, and unlogged manual steps can silently change results over years.
A publication-ready analysis covers five deliverable areas—data, software, documentation, scripts, and delivery—so a second analyst can rerun every figure [5, 11]. Use this table at project kickoff and as acceptance criteria before final payment or manuscript submission.
| Pillar | Minimum requirement |
|---|---|
| Data | Raw FASTQ/BAM archived; metadata in CSV/TSV linked by sample ID; accession IDs in DMSP [8] |
| Software | Version-pinned environment (`environment.yml`, `requirements.txt`, or `renv.lock`); reference build named |
| Documentation | Non-default parameters and random seeds logged [11] |
| Scripts | Version-controlled analysis scripts with step-by-step documentation; avoid irreversible Excel steps for gene lists [7] |
| Delivery | Git repo + README with documented rerun steps; environment file validated on a machine your lab controls |
| Approach | Reproducibility enforcement | Best when |
|---|---|---|
| In-house with SOPs | You own standards; quality often depends on practice and turnover | Continuous pipeline work across grants |
| Academic core facility | SOPs and documentation depth vary with staff and queue pressure | Standard assays with predictable local pricing |
| External bioinformatics CRO | Deliverables can be specified—environment files, Git handoff, milestone criteria | One-off projects, specialist modalities, tight deadlines |
| Sequencing vendor bundle | Often QC-focused; parameter logs and code may be limited | Internal QC—not final manuscript analysis |
Outsourcing does not guarantee reproducibility. Black-box PDF reports without code are a common failure mode. If you outsource, specify deliverables in the statement of work—the bioinformatics CRO guide covers vendor due diligence; this page covers what those deliverables should contain.
Most reproducibility failures are preventable. They show up at peer review or when someone tries to extend the analysis years later.
Cadwallader et al. [12] found 87% code-sharing at PLOS Computational Biology after their policy—but Samuel & Mietchen [1] found only 5.6% of notebooks with declared dependencies actually reproduced identical results.
Ziemann et al. [7] found errors in 30.9% of supplementary Excel gene lists [13].
Piccolo & Frampton [6] cite Nekrutenko & Taylor (2012): fewer than half of 50 NGS papers provided software-version or parameter details.
Version-pinning and script documentation belong at study design, not the week before submission.
Many NGS workflows lack the version and parameter detail needed for independent rerun [6].
Test one figure on a clean machine before processing a full cohort [5, 11].
NIH requires sharing scientific data needed to validate findings, and your DMSP must address related tools, software, and code (effective 25 January 2023) [8]. Code sharing is encouraged but not always mandated for public release.
Wellcome requires an outputs management plan; at a minimum, data underpinning papers and software needed to replicate analyses must be available at publication [9]. UKRI expects open data where possible, with reuse documentation [14].
Nature Portfolio requires custom code central to findings on request and a Code Availability statement at publication; Zenodo or Code Ocean deposition is considered best practice [15].
Reproducibility in bioinformatics means an independent analyst can get consistent results from the same data using the documented scripts, software versions, and parameters. It requires archived raw data, version-pinned software, documented scripts, and logged non-default settings [5, 11]. It is distinct from replicability, which tests whether findings hold when new data is collected under the same protocol.
Computational results depend on software versions, reference genome builds, random seeds, and parameter choices that are easy to change and hard to notice. Samuel & Mietchen [1] found that only 879 of 15,817 biomedical notebooks with declared dependencies produced identical results on automated rerun; most failed with runtime exceptions. A wet-lab protocol fits in a few pages; a transcriptomics pipeline may involve dozens of tools with version-sensitive defaults.
At minimum: raw and processed data files, version-controlled scripts with step-by-step documentation, a version-locked environment (`environment.yml` or `requirements.txt`), a parameter log, figure-generation code tied to stored outputs, and a README with rerun instructions [11]. Specify reference genome builds and random seeds. A PDF report or Excel gene list on its own does not qualify.
You need to retain data sufficient to validate findings—often raw reads plus metadata. Whether public deposition is required depends on funder policy, journal requirements, and participant consent [8, 9]. Controlled-access repositories satisfy many human-subject requirements; reviewers may need access under embargo when public release is delayed.
Reproducibility means rerunning the same analysis on the same data and getting consistent results. Replicability means collecting new data under the same experimental design and getting consistent biological conclusions. Both matter, but bioinformatics projects tend to fail at reproducibility first [2].
The label is debated, but the failure rates are not. Baker [3] found more than 70% of surveyed researchers had tried and failed to reproduce another scientist's experiment. Ioannidis et al. [2] and Zaringhalam & Federer [4] document specific bioinformatics failures. Whatever you call it, the practical consequence is the same: unpublished or contested work when documentation is thin.
No. A conda or venv lock file captures software versions but not undocumented manual steps, missing data, unstated parameters, or wrong random seeds [11]. A pinned environment handles compute-environment control [5]; it is not a substitute for documented scripts, version control, and complete metadata.
Policies vary by journal. Nature Portfolio requires code central to findings on request and a Code Availability statement at publication [15]. Cadwallader et al. [12] found sharing rates at PLOS Computational Biology rose after a mandatory policy, but Samuel & Mietchen [1] show those notebooks still often fail on re-execution. Assume reviewers may try to run your code.
Often yes. NIH requires data sharing for validation and replication; code sharing is encouraged but not universally mandated for public release [8]. Your DMSP must still describe related tools, software, and code access. Many labs share code on request, through controlled repositories, or under embargo. You need runnable artifacts—not necessarily a public GitHub repo on day one.
Request a redacted reproducibility package from a completed project: `environment.yml` or `requirements.txt`, Git repository, documented scripts, and parameter log. Run a paid pilot on a subset of your data before committing to the full cohort. Apply the checklist on this page as milestone acceptance criteria. The bioinformatics CRO guide lists additional vendor questions.
Tell us:
We'll tell you:
Contact us to start with a free consultation. Need everyday bench calculators? Try our free lab tools.